Actively Recruiting
Phase 1 Trial Evaluating PF-08052667 Alone or with BCG andor Sasanlimab for Adults with High-Risk Non-Muscle Invasive Bladder Cancer
Led by Pfizer · Updated on 2026-07-22
294
Participants Needed
68
Research Sites
156 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating how a new medicine called PF-08052667 works alone or in combination with Bacillus Calmette Guerin BCG andor sasanlimab in adults with a type of bladder cancer that has not spread into the muscle layer but has a high risk of recurrence or growth. This study includes adults whose cancer has returned or persisted after standard treatments like BCG, or those who cannot receive such treatments due to medical reasons or availability. The study is a phase 1 trial sponsored by Pfizer focusing on treatment.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
